[(1R)-2-[4-(6-acetamidopyrimidin-4-yl)oxyanilino]-2-oxo-1-phenylethyl] N-tert-butylcarbamate
C25H27N5O5 — CID 175061568
Data last refreshed: (MolForge compound catalog, from PubChem)
About [(1R)-2-[4-(6-acetamidopyrimidin-4-yl)oxyanilino]-2-oxo-1-phenylethyl] N-tert-butylcarbamate
[(1R)-2-[4-(6-acetamidopyrimidin-4-yl)oxyanilino]-2-oxo-1-phenylethyl] N-tert-butylcarbamate (PubChem CID 175061568) has the molecular formula C25H27N5O5 and a molecular weight of 477.52 g/mol. Its IUPAC name is [(1R)-2-[4-(6-acetamidopyrimidin-4-yl)oxyanilino]-2-oxo-1-phenylethyl] N-tert-butylcarbamate.
Molecular Properties
| Compound Name | [(1R)-2-[4-(6-acetamidopyrimidin-4-yl)oxyanilino]-2-oxo-1-phenylethyl] N-tert-butylcarbamate |
|---|---|
| PubChem CID | 175061568 |
| Molecular Formula | C25H27N5O5 |
| Molecular Weight | 477.52 g/mol |
| Exact Mass | 477.20 |
| IUPAC Name | [(1R)-2-[4-(6-acetamidopyrimidin-4-yl)oxyanilino]-2-oxo-1-phenylethyl] N-tert-butylcarbamate |
| SMILES | CC(=O)Nc1cc(Oc2ccc(NC(=O)[C@H](OC(=O)NC(C)(C)C)c3ccccc3)cc2)ncn1 |
| InChI | InChI=1S/C25H27N5O5/c1-16(31)28-20-14-21(27-15-26-20)34-19-12-10-18(11-13-19)29-23(32)22(17-8-6-5-7-9-17)35-24(33)30-25(2,3)4/h5-15,22H,1-4H3,(H,29,32)(H,30,33)(H,26,27,28,31)/t22-/m1/s1 |
| InChIKey | PPKTZYHTJUVTLG-JOCHJYFZSA-N |
| XLogP | 4.43 |
| TPSA | 131.54 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 35 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 477.52 |
| LogP ≤ 5 | 4.43 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 175061568 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.